ZL40, identified as a novel PDE4 inhibitor, exhibited potential in alleviating alcoholic liver damage and reducing inflammation in the NIAAA mice model, making it a promising candidate for ALD treatment, which is characterized by oxidative stress, inflammation, and liver damage due to excessive alcohol consumption. The gene discussed is PDE4A; the disease is alcoholic liver diseases.